Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) COO Matthew Maxwell Donley Sells 65,902 Shares

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) COO Matthew Maxwell Donley sold 65,902 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total transaction of $527,216.00. Following the sale, the chief operating officer now directly owns 739,456 shares of the company’s stock, valued at $5,915,648. The trade was a 8.18 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Aurinia Pharmaceuticals Stock Up 1.3 %

NASDAQ:AUPH traded up $0.10 on Tuesday, reaching $8.08. 3,640,172 shares of the stock traded hands, compared to its average volume of 1,449,999. The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of -53.86 and a beta of 1.22. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17. Aurinia Pharmaceuticals Inc. has a 12 month low of $4.71 and a 12 month high of $10.67. The company’s fifty day simple moving average is $8.13 and its 200 day simple moving average is $7.85.

Analyst Upgrades and Downgrades

Separately, StockNews.com cut shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 19th.

Institutional Trading of Aurinia Pharmaceuticals

A number of large investors have recently made changes to their positions in AUPH. Tang Capital Management LLC grew its stake in shares of Aurinia Pharmaceuticals by 16.6% in the fourth quarter. Tang Capital Management LLC now owns 8,429,500 shares of the biotechnology company’s stock worth $75,697,000 after acquiring an additional 1,200,000 shares during the period. Arrowstreet Capital Limited Partnership bought a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter worth approximately $9,662,000. Point72 Asset Management L.P. bought a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter worth approximately $7,630,000. Lazard Asset Management LLC boosted its holdings in shares of Aurinia Pharmaceuticals by 341.9% in the fourth quarter. Lazard Asset Management LLC now owns 596,389 shares of the biotechnology company’s stock worth $5,355,000 after buying an additional 461,430 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Aurinia Pharmaceuticals in the third quarter worth approximately $3,330,000. 36.83% of the stock is currently owned by institutional investors.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.